Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02116543 | TD-6450 MAD Study in HCV Infected Subjects | PHASE1 | COMPLETED | 47 | — | — | May 1, 2014 | Nov 1, 2014 | Jan 19, 2021 | 1 | United States |
| NCT02022306 | TD-6450 SAD and MAD in Healthy Subjects | PHASE1 | COMPLETED | 111 | — | — | Feb 1, 2014 | Sep 1, 2014 | Jan 14, 2021 | 1 | United States |
Number, type, severity, and association of treatment emergent adverse events.
| Arm | Type | Description |
|---|---|---|
| TD-6450 | EXPERIMENTAL | TD-6450 capsules |
| Placebo | PLACEBO_COMPARATOR | Placebo capsules |
| SAD TD-6450 | PLACEBO_COMPARATOR | Single ascending dose (Part A) |
| MAD TD-6450 | PLACEBO_COMPARATOR | Multiple ascending dose (Part B) |
| Food effect of TD-6450 | ACTIVE_COMPARATOR | Food effect will be assessed in Part A (SAD) of this study. |
| Name | Type | Description |
|---|---|---|
| TD-6450 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Subject is HCV antibody positive * Subject is treatment naïve, with no history of exposure (single or multiple dose) to interferon, ribavirin or direct acting antivirals. * Subject has had a liver biopsy within 3 years or Fibroscan evaluation within 6 months prior to Screening...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir |
| Abbott Laboratories | ABT | 2 | — | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | — | Undisclosed |